Journal Home
Search for

Volume 104, Issue 7, Pages 1005-1011 (July 2010)


View previous. 11 of 25 View next.

Physical inactivity in patients with COPD, a controlled multi-center pilot-study

Thierry TroostersabCorresponding Author Informationhemail address, Frank Sciurbac, Salvatore Battagliad, Daniel Langerabh, Srinivas Rao Vallurie, Lavinia Martinod, Roberto Benzoc, David Andref, Idelle Weismang, Marc Decramerab

Received 8 July 2009; accepted 15 January 2010. published online 18 February 2010.

Summary 

Background

Physical activity (PA) has been reported to be reduced in severe chronic obstructive pulmonary disease (COPD). Studies in moderate COPD are currently scarce. The aim of the present study was to investigate physical activity in daily life in patients with COPD (n=70) and controls (n=30).

Methods

A multi-center controlled study was conducted. PA was assessed using a multisensor armband device (SenseWear, BodyMedia, Pittsburgh, PA) and is reported as the average number of steps per day, and the time spent in mild and moderate physical activity.

Results

Patients suffered from mild (n=9), moderate (n=28), severe (n=23) and very severe (n=10) COPD. The time spent in activities with mild (80±69min vs 160±89min, p<0.0001) and moderate intensity (24±29min vs 65±70min; p<0.0036) was reduced in patients compared to controls. The number of steps reached 87±34%, 71±32%, 49±34% and 29±20% of control values in GOLD-stages I to IV respectively. The time spent in activities at moderate intensity was 53±47%, 41±45%, 31±47% and 22±34% of the values obtained in controls respectively with increasing GOLD-stage. These differences reached statistical significance as of GOLD stage II (p<0.05). No differences were observed among centers.

Conclusions

Physical activity is reduced early in the disease progression (as of GOLD-stage II). Reductions in physical activities at moderate intensity seem to precede the reduction in the amount of physical activities at lower intensity.

a Pulmonary Rehabilitation and Respiratory Division, UZ Gasthuisberg, Leuven, Belgium

b Faculty of Kinesiology and Rehabilitation Sciences, Katholieke Universiteit Leuven, Leuven, Belgium

c Division of Pulmonary & Critical Care Mayo Clinic, Rochester, MN, USA

d Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy

e Specialty Care Business Unit, Pfizer Inc, New York, NY, USA

f BodyMedia Inc, Pittsburgh, PA, USA

g Medical Affairs- Respiratory, Global Primary Care Business Unit, Pfizer Inc, New York, NY

Corresponding Author InformationCorresponding author. UZ Gasthuisberg, Respiratory Division, Herestraat 49, B3000 Leuven, Belgium.

h TT and DL are (post)doctoral fellows of the Research Foundation Flanders. Grants: This study was funded through an independent research grant from Pfizer Inc (New York, NY) in collaboration with BodyMedia Inc (Pittsburgh, PA).

PII: S0954-6111(10)00037-5

doi:10.1016/j.rmed.2010.01.012


View previous. 11 of 25 View next.